Delivery Order SPE2DB22D2206-SPE2DB25FJD68
- Not listed
- The Defense Logistics Agency awarded a $17,257.88 delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Enbrel 50 mg/ml syringes. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order valued at $9,158.68 to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes, with a completion date of June 20, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, supporting federal military and...
- The Defense Logistics Agency awarded a $13,737.99 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL syringes, with an ultimate completion date of September 12, 2025. This contract represents a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and operates as a child contract...
- The Defense Logistics Agency awarded a $10,359.88 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of September 16, 2025. The contract was competitively awarded with no set-aside designation and is structured as a firm fixed-price delivery order. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,677.38 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL syringes, with performance in Conshohocken, Pennsylvania and completion targeted for September 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $9,158.68 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. The contract is a firm fixed price delivery order with an ultimate completion date of August 1, 2025, and was awarded on July 31, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was used for this competitive award. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes valued at $68,950.48 on September 12, 2025, with completion targeted for September 15, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling and extends through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $9,806.98 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes, with an ultimate completion date of September 17, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The contract was executed on September 16, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility, the company's corporate headquarters....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for ENBREL 50 mg/ml syringes valued at $29,284.84. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order will be fulfilled at the contractor's Conshohocken, Pennsylvania facility with...
- The Defense Logistics Agency awarded a $14.5K delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of ENBREL 25 mg/0.5 ml syringes. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJD68Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,168.81 to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to AmerisourceBergen's Corporate Office located in Conshohocken, Pennsylvania. The contract represents a continuation of pharmaceutical supply delivery under AmerisourceBergen's broader federal contracting relationship with the DLA. This delivery order is executed under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vendor contract running through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare systems worldwide. As a critical vendor for federal medical procurement, AmerisourceBergen supplies an extensive portfolio of pharmaceutical products including specialty medications, brand-name and generic drugs, and medical devices across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The current delivery order for Enbrel, a biologic medication used primarily for rheumatoid arthritis and other autoimmune conditions, demonstrates the company's ongoing role in fulfilling specialized pharmaceutical requirements for the federal healthcare supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.2k | 7/30/25 |